Stock LASA LASA SUPERGENERICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lasa Supergenerics Limited

Equities

LASA

INE670X01014

Pharmaceuticals

End-of-day quote NSE India S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
21.2 INR -4.07% Intraday chart for Lasa Supergenerics Limited -7.63% -29.10%
Apr. 26 Lasa Supergenerics CFO Steps Down MT
Apr. 26 Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,061 508.7 1,106 2,432 1,700 929.4
Enterprise Value (EV) 1 3,123 1,350 1,565 2,588 1,730 1,125
P/E ratio 16.6 x -4.23 x 30.6 x 10.7 x -31.7 x -2.41 x
Yield - - - 0.42% 0.6% -
Capitalization / Revenue 0.85 x 0.3 x 0.66 x 1.2 x 1.24 x 0.72 x
EV / Revenue 1.28 x 0.8 x 0.94 x 1.28 x 1.26 x 0.87 x
EV / EBITDA 7.57 x 11.9 x 4.75 x 5.48 x 10.5 x -24 x
EV / FCF -13.3 x 5.02 x 21.1 x 12.9 x 7.52 x 7.99 x
FCF Yield -7.51% 19.9% 4.73% 7.76% 13.3% 12.5%
Price to Book 1.76 x 0.48 x 0.78 x 1.53 x 1.14 x 0.79 x
Nbr of stocks (in thousands) 22,864 22,864 40,673 40,673 40,673 50,101
Reference price 2 90.15 22.25 27.20 59.80 41.80 18.55
Announcement Date 9/6/18 9/6/19 9/3/20 9/1/21 9/2/22 9/4/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 2,435 1,696 1,673 2,024 1,371 1,296
EBITDA 1 412.6 113.5 329.2 472.7 164.7 -46.8
EBIT 1 231 -79.56 155.8 314.4 24.72 -181
Operating Margin 9.48% -4.69% 9.32% 15.54% 1.8% -13.97%
Earnings before Tax (EBT) 1 152.3 -161 47.36 294.9 -62.1 -422.7
Net income 1 123.4 -120.3 36.28 227.8 -53.67 -386.2
Net margin 5.07% -7.09% 2.17% 11.25% -3.91% -29.81%
EPS 2 5.429 -5.262 0.8900 5.600 -1.320 -7.710
Free Cash Flow 1 -234.5 269 74.08 200.8 230.2 140.8
FCF margin -9.63% 15.86% 4.43% 9.92% 16.79% 10.87%
FCF Conversion (EBITDA) - 236.94% 22.5% 42.49% 139.76% -
FCF Conversion (Net income) - - 204.16% 88.17% - -
Dividend per Share - - - 0.2500 0.2500 -
Announcement Date 9/6/18 9/6/19 9/3/20 9/1/21 9/2/22 9/4/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 1,062 842 458 156 29.8 196
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.573 x 7.415 x 1.393 x 0.3306 x 0.1809 x -4.187 x
Free Cash Flow 1 -234 269 74.1 201 230 141
ROE (net income / shareholders' equity) 12.8% -10.8% 2.94% 15.2% -3.49% -28%
ROA (Net income/ Total Assets) 5.61% -1.82% 3.97% 8.94% 0.76% -6.06%
Assets 1 2,201 6,596 913.7 2,549 -7,072 6,368
Book Value Per Share 2 51.30 46.10 34.80 39.10 36.50 23.60
Cash Flow per Share 2 0.2200 0.1800 0.6300 0.9400 2.710 0.4300
Capex 1 467 113 6.27 65.9 - -
Capex / Sales 19.18% 6.68% 0.37% 3.25% - -
Announcement Date 9/6/18 9/6/19 9/3/20 9/1/21 9/2/22 9/4/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Veterinary Drugs

1st Jan change Capi.
LASA SUPERGENERICS LIMITED Stock Lasa Supergenerics Limited
-29.10% 13.29M
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
+18.66% 8.7B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+23.75% 3.71B
VIRBAC Stock Virbac
-0.42% 3.21B
VIMIAN GROUP AB Stock Vimian Group AB
+18.07% 1.66B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-16.99% 1.43B
VETOQUINOL SA Stock Vetoquinol SA
-0.39% 1.3B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-26.05% 1.25B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-17.86% 1.09B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-6.77% 979M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. LASA Stock
  4. Financials Lasa Supergenerics Limited